Jefferies raises Becton Dickinson stock price target on guidance
Jefferies raised its price target on Becton Dickinson (BDX) to $242 from $210, citing strong Q4 results and guidance. BDX reported $5.27B in sales, up 5.6%, and EPS of $4.15, up 27%. The company projected fiscal 2027 sales growth of low single digits and EPS of $13.10-$13.30. Jefferies views the guidance as conservative and sees potential upside. BDX stock has surged 55% over the past year.
How this was made
The 30-second read
Why it matters
The upgrade may attract new buying interest and support the stock near its 52‑week high.
Market read
Analyst target raise provides fresh actionable insight for traders in BDX.
What to watch
Potential tariff relief and Alaris hardware impact could be less material than assumed.
Background
Jefferies upgraded BDX to a Buy with a higher price target following better‑than‑expected Q4 earnings and FY2027 guidance.
Ticker impact
Jefferies raised its price target on Becton Dickinson (BDX) to $242 from $210 after the company reported Q4 results and issued FY2027 guidance.
likely upward pressure as the market prices in the higher target
The new target is $32 above the current price, indicating the analyst sees further upside.
Market effects
Positive signal for the medical technology sector as a leading supplier raises outlook.
U.S. healthcare stocks may see modest gains.
Limited to investors tracking US med‑tech equities.
Counterpoint
The target raise may already be priced in; the stock could face short‑term profit‑taking.
Key entities
- companyBecton Dickinson
Medical technology firm (ticker BDX).
- analystJefferies
Investment bank that issued the price‑target raise.
